Cancer drugs drive Roche sales in 2012

European sales decline.

New Statesman
Severin Schwan, CEO of Roche. Credit: Getty Images.

The Swiss health-care company Roche has posted revenues of 45.5bn Swiss francs for the year ended 31 December 2012, an increase of 4 per cent compared to 42.5bn Swiss francs for the same period a year ago.

The company’s sales in the US market grew 7 per cent, while sales in European market fell by 2 per cent. Meanwhile, Roche’s smaller diagnostics division improved revenue by 4 per cent.

The group’s net profit increased by 2.4 per cent to 9.8bn Swiss francs in 2012.

Due to growing demand for its Avastin and Herceptin cancer drugs, Roche’s core pharmaceuticals division improved revenues by 5 per cent. The division also benefited from the introduction of breast cancer drug Perjeta.

During the year, Roche had seen 11 positive results from 14 late stage drugs trials, as well as, launched three new cancer drugs.

Severin Schwan, CEO of Roche, said equated to a “very good year”, the group plans to increase its dividend by 8 per cent to 7.35 Swiss franc per share.

The company expects its earnings per share and sales to rise in 2013.